340B Duplicate Discount Prevention

 Move away from "pay and chase" model to front-end validation and prevention.  Recovery-based approaches and platforms still leave manufacturers with substantial amount of heavy lifting through the disputed claims.

Eligibility certified using additional CE provided data. Reliable and validated data with multi-source cross referencing. Additional wholesaler data allows OptivanceX to trace a claim back to its wholesale invoice for accurate eligibility determination, purchase accumulation and dispute resolution.

Platform does not rely on JG/TB modifiers which often are missing or incorrect. A core data transparency gap in the current program is the lack of 340B modifier for Part D drugs and little enforcement for recently established Part B modifier

Tungsten+ R™ identifies Medicaid eligibility to prevent duplicate payments. Highly accurate identification leads to reduced inquiry and dispute burdens at the source. Detection and prevention early on means fewer overall disputes.